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1) Describe the clinical presentation of disseminated
cryptococcosis
2) Discuss the appropriate treatment of disseminated
cryptococcosis
A 52-year-old man with HIV/AIDS and recent CD4+ T-cell
count of 11/µL (CD4+ percent of 3%) presented with
shortness of breath and non-productive cough for 3
months. He was otherwise asymptomatic, denying
headaches, photophobia, fevers, chills, night sweats, and
hemoptysis. He had no concerning environmental
exposures, and denied tobacco, alcohol, and recreational
drug use. Medications included darunavir/cobicistat and
emtricitabine/tenofovir.
Physical Exam:
Vital signs and physical examination were normal with the
exception of several 1 mm umbilicated flesh-toned non-
tender papules spread across his face.
Labs:
Laboratory analysis revealed a positive Cryptococcal
serum antigen titer of 1:16,000 and CSF antigen titer of
1:32,000.
Treatment:
The patient was treated with a combination of
amphotericin B and flucytosine with improvement in his
facial rash, symptoms, and Cryptococcal antigen titer.
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This case demonstrates an AIDS patient with disseminated 
cryptococcosis who presented with pulmonary and 
meningeal involvement, and was found to have 
endobronchial lesions harboring Cryptococcus neoformans
and cutaneous umbilicated papules across his face. 
Although these findings are typical, disseminated 
Cryptococcosis was more common in the pre-HAART era, 
and today’s physicians may not readily identify it.
Cryptococcal infections primarily affect the lungs, however 
the most common extrapulmonary site of infection is the 
central nervous system, often seen in patients with AIDS. In 
these patients, management includes long-term treatment 
with anti-fungal medications, as in the table below.
Anti-retroviral medications are typically held for five weeks 
after initiation of anti-fungal therapy to decrease the risk of 
immune reconstitution inflammatory syndrome (IRIS). 
Interestingly, our patient had started anti-retroviral therapy 
for several weeks prior to admission, which may have 
precipitated an immune reconstitution phenomenon, 
causing his presenting symptom.
A                                                                       B
Figure 3.  A: Biopsy of right mainstem endobronchus with mucicarmine staining 
showing Cryptococcus neoformans. B: Biopsy of right mainstem endobronchus with 
mucicarmine staining showing Cryptococcus neoformans (higher power).
Imaging:
Chest X-ray on admission showed a diffuse reticular
pattern. Computed tomography of the thorax without
contrast showed a tree-in-bud nodularity pattern with
peribronchovascular thickening in addition to a large
cavitary lesion within the right lower lobe.
A                                                                       B
Figure 2.  A: CT scan of patient’s chest showing evidence of a cavitary lesion. B: 
Bronchoscopy image demonstrating ulcerated lesions on patient’s endobronchus.
Pathology: 
Bronchoscopy showed ulcerated erythematous
endobronchial plaques within the right segmental
bronchi. The lesions were biopsied and mucicarmine
stain revealed diffuse encapsulated yeast forms.
Cryptococcus neoformans was cultured from
bronchioalveolar lavage fluid, cerebrospinal fluid, and
blood.
A                                                                         B
Figure 1.  A: Cutaneous lesions due to disseminated Cryptococcosis (patient’s 
forehead). B: India ink staining of CSF fluid demonstrating Cryptococcal organisms.










2 weeks, or until CSF 
cultures negative
10 weeks
Until CD4+ count is 
above 200/µL for 6 
months
